IOB - Delayed Quote USD

Moderna, Inc. (0A45.IL)

Compare
33.22
-9.65
(-22.51%)
At close: 5:51:32 PM GMT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephane Bancel CEO & Director 4.97M 392.58M 1973
Dr. Stephen Hoge M.D. Pres 2.41M 56.52M 1976
Mr. James M. Mock Chief Financial Officer 1.49M -- 1977
Ms. Arpa Garay Chief Commercial Officer 2.67M -- 1979
Dr. Jerh Collins Ph.D. Chief Technical Operations & Quality Officer -- -- 1966
Dr. Melissa J. Moore Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board -- -- --
Mr. Brad Miller Chief Information Officer -- -- 1973
Ms. Lavina Talukdar CFA Sr. VP & Head of Investor Relations -- -- --
Ms. Shannon Thyme Klinger Chief Legal Officer & Corp. Sec. -- -- 1971
Colleen Hussey Sr. Director of Corp. Communications -- -- --

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500 https://www.modernatx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
3,900

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of October 1, 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 20, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC

Moderna, Inc. Earnings Date

Recent Events

Related Tickers